Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis

Anton L. Pozniak; Joel E. Gallant; Edwin DeJesus; Jose R. Arribas; Brian Gazzard; Rafael E. Campo; Shan Shan Chen; Damian McColl; Jeffrey Enejosa; John J. Toole; Andrew K. Cheng

doi:10.1097/01.qai.0000245886.51262.67

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis

Anton L. Pozniak, Joel E. Gallant, Edwin DeJesus, Jose R. Arribas, Brian Gazzard, Rafael E. Campo, Shan Shan Chen, Damian McColl, Jeffrey Enejosa, John J. Toole, Andrew K. Cheng

School of Medicine

Research output: Contribution to journal › Article › peer-review

198 Scopus citations

Abstract

BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received TDF, FTC, and EFV (TDF + FTC + EFV) or ZDV/3TC and EFV (ZDV/3TC + EFV). The primary endpoint was the proportion of patients with an HIV RNA level

Original language	English (US)
Pages (from-to)	535-540
Number of pages	6
Journal	Journal of Acquired Immune Deficiency Syndromes
Volume	43
Issue number	5
DOIs	https://doi.org/10.1097/01.qai.0000245886.51262.67
State	Published - Dec 2006

Keywords

Antiretroviral naive
Emtricitabine
Lamivudine
Lipoatrophy
Tenofovir
Zidovudine

ASJC Scopus subject areas

Virology
Immunology

Access to Document

10.1097/01.qai.0000245886.51262.67

Fingerprint

Dive into the research topics of 'Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis'. Together they form a unique fingerprint.

Cite this

Pozniak, A. L., Gallant, J. E., DeJesus, E., Arribas, J. R., Gazzard, B., Campo, R. E., Chen, S. S., McColl, D., Enejosa, J., Toole, J. J., & Cheng, A. K. (2006). Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis. Journal of Acquired Immune Deficiency Syndromes, 43(5), 535-540. https://doi.org/10.1097/01.qai.0000245886.51262.67

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis. / Pozniak, Anton L.; Gallant, Joel E.; DeJesus, Edwin et al.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 5, 12.2006, p. 535-540.

Research output: Contribution to journal › Article › peer-review

Pozniak, AL, Gallant, JE, DeJesus, E, Arribas, JR, Gazzard, B, Campo, RE, Chen, SS, McColl, D, Enejosa, J, Toole, JJ & Cheng, AK 2006, 'Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis', Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 5, pp. 535-540. https://doi.org/10.1097/01.qai.0000245886.51262.67

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis. Journal of Acquired Immune Deficiency Syndromes. 2006 Dec;43(5):535-540. doi: 10.1097/01.qai.0000245886.51262.67

Pozniak, Anton L. ; Gallant, Joel E. ; DeJesus, Edwin et al. / Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients : Virologic, immunologic, and morphologic changes - A 96-week analysis. In: Journal of Acquired Immune Deficiency Syndromes. 2006 ; Vol. 43, No. 5. pp. 535-540.

@article{c8b4c4900bca4b019d4672076ff7e135,

title = "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis",

abstract = "BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received TDF, FTC, and EFV (TDF + FTC + EFV) or ZDV/3TC and EFV (ZDV/3TC + EFV). The primary endpoint was the proportion of patients with an HIV RNA level ",

keywords = "Antiretroviral naive, Emtricitabine, Lamivudine, Lipoatrophy, Tenofovir, Zidovudine",

author = "Pozniak, {Anton L.} and Gallant, {Joel E.} and Edwin DeJesus and Arribas, {Jose R.} and Brian Gazzard and Campo, {Rafael E.} and Chen, {Shan Shan} and Damian McColl and Jeffrey Enejosa and Toole, {John J.} and Cheng, {Andrew K.}",

year = "2006",

month = dec,

doi = "10.1097/01.qai.0000245886.51262.67",

language = "English (US)",

volume = "43",

pages = "535--540",

journal = "Journal of Acquired Immune Deficiency Syndromes",

issn = "1525-4135",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients

T2 - Virologic, immunologic, and morphologic changes - A 96-week analysis

AU - Pozniak, Anton L.

AU - Gallant, Joel E.

AU - DeJesus, Edwin

AU - Arribas, Jose R.

AU - Gazzard, Brian

AU - Campo, Rafael E.

AU - Chen, Shan Shan

AU - McColl, Damian

AU - Enejosa, Jeffrey

AU - Toole, John J.

AU - Cheng, Andrew K.

PY - 2006/12

Y1 - 2006/12

N2 - BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received TDF, FTC, and EFV (TDF + FTC + EFV) or ZDV/3TC and EFV (ZDV/3TC + EFV). The primary endpoint was the proportion of patients with an HIV RNA level

AB - BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received TDF, FTC, and EFV (TDF + FTC + EFV) or ZDV/3TC and EFV (ZDV/3TC + EFV). The primary endpoint was the proportion of patients with an HIV RNA level

KW - Antiretroviral naive

KW - Emtricitabine

KW - Lamivudine

KW - Lipoatrophy

KW - Tenofovir

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=33845354174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845354174&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000245886.51262.67

DO - 10.1097/01.qai.0000245886.51262.67

M3 - Article

C2 - 17057609

AN - SCOPUS:33845354174

SN - 1525-4135

VL - 43

SP - 535

EP - 540

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

IS - 5

ER -

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this